- Home
- AES vs ROIV Comparison
AES vs ROIV Comparison
Compare AES & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | ROIV |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 14.1B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | AES | ROIV |
|---|---|---|
| Price | $13.84 | $21.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $15.70 | ★ $21.94 |
| AVG Volume (30 Days) | ★ 7.0M | 6.5M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $12,094,000,000.00 | $20,329,000.00 |
| Revenue This Year | $1.13 | N/A |
| Revenue Next Year | $4.33 | $376.94 |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.46 | $8.73 |
| 52 Week High | $15.51 | $22.45 |
Technical Indicators
Market Signals| Indicator | AES | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 68.21 |
| Support Level | $13.66 | $20.14 |
| Resistance Level | $14.20 | $21.48 |
| Average True Range (ATR) | 0.29 | 0.66 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 29.36 | 87.12 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.